These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38725705)

  • 1. Virologic outcomes with tenofovir-lamivudine-dolutegravir in adults failing PI-based second-line ART.
    Zhao Y; Voget J; Singini I; Omar Z; Mudaly V; Boulle A; Maartens G; Meintjes G
    South Afr J HIV Med; 2024; 25(1):1567. PubMed ID: 38725705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.
    Keene CM; Griesel R; Zhao Y; Gcwabe Z; Sayed K; Hill A; Cassidy T; Ngwenya O; Jackson A; van Zyl G; Schutz C; Goliath R; Flowers T; Goemaere E; Wiesner L; Simmons B; Maartens G; Meintjes G
    AIDS; 2021 Jul; 35(9):1423-1432. PubMed ID: 33973876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
    Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Asienzo J; Kaimal A; Mirembe G; Lugemwa A; Ategeka G; Borok M; Mugerwa H; Siika A; Odongpiny ELA; Castelnuovo B; Kiragga A; Kambugu A;
    Lancet HIV; 2022 Jun; 9(6):e381-e393. PubMed ID: 35460601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens.
    Fokam J; Chenwi CA; Takou D; Santoro MM; Tala V; Teto G; Beloumou G; Semengue ENJ; Dambaya B; Djupsa S; Kembou E; Bouba NP; Ajeh R; Cappelli G; Mbanya D; Colizzi V; Ceccherini-Silberstein F; Perno CF; Ndjolo A
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial.
    Zhao Y; Keene C; Griesel R; Sayed K; Gcwabe Z; Jackson A; Ngwenya O; Schutz C; Goliath R; Cassidy T; Goemaere E; Hill A; Maartens G; Meintjes G
    Wellcome Open Res; 2021; 6():33. PubMed ID: 36017341
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
    Kouamou V; Manasa J; Katzenstein D; McGregor AM; Ndhlovu CE; Makadzange AT
    AIDS; 2019 Sep; 33(11):1729-1737. PubMed ID: 31361272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe.
    Chimbetete C; Katzenstein D; Shamu T; Spoerri A; Estill J; Egger M; Keiser O
    Open Forum Infect Dis; 2018 Feb; 5(2):ofy005. PubMed ID: 29435471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
    De Wit S; Bonnet F; Osiyemi O; Bisshop F; Olalla J; Routy JP; Wyen C; Moodley R; Pappa K; Wang R; Oyee J; Saggu P; Letang E; Wynne B; Jones B; Smith KY; Ait-Khaled M
    J Acquir Immune Defic Syndr; 2024 Mar; ():. PubMed ID: 38346427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
    Zhao Y; Griesel R; Omar Z; Simmons B; Hill A; van Zyl G; Keene C; Maartens G; Meintjes G
    Clin Infect Dis; 2023 May; 76(10):1832-1840. PubMed ID: 36645792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.
    Keene CM; Cassidy T; Zhao Y; Griesel R; Jackson A; Sayed K; Omar Z; Hill A; Ngwenya O; Van Zyl G; Flowers T; Goemaere E; Maartens G; Meintjes G
    J Acquir Immune Defic Syndr; 2023 Apr; 92(5):422-429. PubMed ID: 36706364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study.
    Allahna E; Nicole D; Neha S; Hannah K; Jonah M; John O; Valentine S; Emmanuel B; Michael I; Trevor A C; Christina S P; Joseph S C; Julie A A;
    J Acquir Immune Defic Syndr; 2022 Nov; 91(3):285-289. PubMed ID: 35980350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment.
    Steegen K; Levin L; Evans D; Technau KG; Hans L
    Pediatr Infect Dis J; 2022 Oct; 41(10):827-834. PubMed ID: 35895893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
    Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
    J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
    Osiyemi O; De Wit S; Ajana F; Bisshop F; Portilla J; Routy JP; Wyen C; Ait-Khaled M; Leone P; Pappa KA; Wang R; Wright J; George N; Wynne B; Aboud M; van Wyk J; Smith KY
    Clin Infect Dis; 2022 Sep; 75(6):975-986. PubMed ID: 35079789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale.
    Kouamou V; Machekano R; Mapangisana T; Maposhere C; Munyati S; Mutsvangwa J; Shamu T; McCarty K; Katzenstein D; Manasa J
    AIDS Res Hum Retroviruses; 2022 Oct; 38(10):774-778. PubMed ID: 35959737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data.
    Sangaré MN; Baril JG; de Pokomandy A; Ferreira Guerra S; Carabali M; Laprise C; Thomas R; Klein M; Tremblay C; Roger M; Pexos C; Greenwald ZR; Machouf N; Durand M; Hardy I; Dakouo M; Trevisan A; Laporte L; Schnitzer ME; Trottier H
    Open Forum Infect Dis; 2020 Nov; 7(11):ofaa404. PubMed ID: 33204746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment.
    Kouamou V; Varyani B; Shamu T; Mapangisana T; Chimbetete C; Mudzviti T; Manasa J; Katzenstein D
    AIDS Res Hum Retroviruses; 2020 Jul; 36(7):566-573. PubMed ID: 32138527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
    Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
    Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
    Borghetti A; Lombardi F; Gagliardini R; Baldin G; Ciccullo A; Moschese D; Emiliozzi A; Belmonti S; Lamonica S; Montagnani F; Visconti E; De Luca A; Di Giambenedetto S
    BMC Infect Dis; 2019 Jan; 19(1):59. PubMed ID: 30654739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.